As of 02/05/2026, no clinical trials have been completed testing the efficacy of GLP-1RAs (GLP-1 RAs) in treating opioid use disorder (OUD), cocaine use disorder, or other stimulant use disorders
Downstream effectors: mTOR, FOXO, and the atrophyhypertrophy balance Following the PI3K/Akt activation described above, several effectors determine the biological readout
Heres where weve narrowed down the results
At TrimRx, our programs are built around the idea that medication is a bridge to a healthier lifestyle, not a replacement for it
Nutrition and cleansing are both essential for neurotransmitter rehabilitation
Gastrointestinal symptoms represent the most frequently reported adverse effects of GLP-1 medications, including: Nausea and vomiting (very common, affecting up to 44% of patients in clinical trials for semaglutide 2